Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01)

Funding Opportunity PAR-16-111 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding